OBJECTIVE: To gather information about cytomegalovirus (CMV) prevention and treatment practices in bone marrow transplantation (BMT) in Canada. DESIGN: A questionnaire was mailed to all centres across Canada performing BMT in January 1998. A second mailing was sent three months later. POPULATION STUDIED: Data on 15 centres performing allogeneic BMT (total patients 459) and 16 centres (total patients 703) performing autologous BMT were obtained. RESULTS: For allogeneic BMT, all donors and recipients had pretransplant CMV serology performed. Nine centres gave CMV-negative blood to only donor-negative/recipient-negative patients, four centres to all patients and two centres to other subgroups. All allogeneic BMT centres had a strategy for CMV prevention. Three centres used universal ganciclovir prophylaxis, while 12 centres used some form of pre-emptive ganciclovir therapy based on weekly antigenemia assays (four centres), weekly polymerase chain reaction (two centres), CMV blood cultures (one centre), CMV throat and urine cultures (one centre), CMV screening bronchoscopy (two centres), or a combination of antigenemia plus bronchoscopy (two centres). The dose and duration of pre-emptive ganciclovir varied considerably from centre to centre. In addition, many centres used high dose acyclovir universally for a variable period of time post-BMT. For the treatment of CMV pneumonia, 14 centres used ganciclovir plus immunoglobulin (IG) and one centre used ganciclovir alone. Ganciclovir treatment duration ranged from two to 11 weeks and the number of doses of IG from three to 18. Thirteen of 16 autologous BMT centres screened patients for CMV pretransplant. Ten centres used CMV negative blood for some or all of their patients. Only one centre performed routine CMV monitoring after autologous BMT. CONCLUSIONS: Practices for the prevention of CMV disease in BMT patients differ widely across centres, and further data may assist in developing a consensus regarding the optimal approach to CMV management.
OBJECTIVE: To gather information about cytomegalovirus (CMV) prevention and treatment practices in bone marrow transplantation (BMT) in Canada. DESIGN: A questionnaire was mailed to all centres across Canada performing BMT in January 1998. A second mailing was sent three months later. POPULATION STUDIED: Data on 15 centres performing allogeneic BMT (total patients 459) and 16 centres (total patients 703) performing autologous BMT were obtained. RESULTS: For allogeneic BMT, all donors and recipients had pretransplant CMV serology performed. Nine centres gave CMV-negative blood to only donor-negative/recipient-negative patients, four centres to all patients and two centres to other subgroups. All allogeneic BMT centres had a strategy for CMV prevention. Three centres used universal ganciclovir prophylaxis, while 12 centres used some form of pre-emptive ganciclovir therapy based on weekly antigenemia assays (four centres), weekly polymerase chain reaction (two centres), CMV blood cultures (one centre), CMV throat and urine cultures (one centre), CMV screening bronchoscopy (two centres), or a combination of antigenemia plus bronchoscopy (two centres). The dose and duration of pre-emptive ganciclovir varied considerably from centre to centre. In addition, many centres used high dose acyclovir universally for a variable period of time post-BMT. For the treatment of CMV pneumonia, 14 centres used ganciclovir plus immunoglobulin (IG) and one centre used ganciclovir alone. Ganciclovir treatment duration ranged from two to 11 weeks and the number of doses of IG from three to 18. Thirteen of 16 autologous BMT centres screened patients for CMV pretransplant. Ten centres used CMV negative blood for some or all of their patients. Only one centre performed routine CMV monitoring after autologous BMT. CONCLUSIONS: Practices for the prevention of CMV disease in BMT patients differ widely across centres, and further data may assist in developing a consensus regarding the optimal approach to CMV management.
Entities:
Keywords:
Bone marrow transplantation; Cytomegalovirus
Authors: H Hebart; A Schröder; J Löffler; T Klingebiel; H Martin; B Wassmann; F Gerneth; H Rabenau; G Jahn; L Kanz; C A Müller; H Einsele Journal: J Infect Dis Date: 1997-06 Impact factor: 5.226
Authors: P Ljungman; R De Bock; C Cordonnier; H Einsele; D Engelhard; J Grundy; A Locasciulli; P Reusser; P Ribaud Journal: Bone Marrow Transplant Date: 1993-10 Impact factor: 5.483
Authors: D J Winston; W G Ho; K Bartoni; C Du Mond; D F Ebeling; W C Buhles; R E Champlin Journal: Ann Intern Med Date: 1993-02-01 Impact factor: 25.391
Authors: J R Wingard; D Y Chen; W H Burns; D J Fuller; H G Braine; A M Yeager; H Kaiser; P J Burke; M L Graham; G W Santos Journal: Blood Date: 1988-05 Impact factor: 22.113